Kenji Fujita

Company: Atsena Therapeutics

Job title: Chief Medical Executive

Seminars:

Exploring XLRS Cohort Update: Dosing, Safety, and Efficacy Insights 12:00 pm

Explore dosing strategies employed within the XLRS cohort, analyzing the rationale behind dosage adjustments and their impact on treatment outcomes Examine the safety profile observed during the trial, highlighting any notable findings and addressing concerns regarding adverse events Dissect the efficacy data gleaned from the XLRS cohort, presenting key findings and potential implications for patient…Read more

day: Day Two 12th

Panel Discussion: Maximizing Ophthalmic Gene Therapy Trial Success Strategies 9:30 am

Discussing strategies for improving trial design to mitigate risks and enhance success Exploring the regulatory landscape and its impact on gene therapy trials, including approval processes and compliance requirements Detailing actionable steps derived from past failures to inform future gene therapy endeavours and maximize trial outcomesRead more

day: Day Two 12th